Kari Blaho-Owens

Kari Blaho-Owens, Ph.D., received her graduate degree in pharmacology and clinical therapeutics from LSU Medical Center in New Orleans, Louisiana, US. She was the Research Director and clinical toxicologist consultant in an inner-city Emergency Department at UT College of Medicine and has spent much of her career in the life sciences industry working for pharmaceutical and device companies, as well as CROs. She also served as the global head of PV at a major company. Kari is currently the head of PV at Perficient, where she leads a team that implements fit-for-purpose technology solutions and provides pharmacovigilance consulting. She is also a peer reviewer for the DIA.

Blogs from this Author


The Future of Pharmacovigilance

Previously, I discussed how pharmacovigilance can work, when implemented correctly. In the final installment of this blog series, I look at the future of pharmacovigilance. How can you close the knowledge gap and move pharmacovigilance from a state of reactive to proactive? While the presented earlier is merely an example, it is based on real […]


Why Proactive Pharmacovigilance Can Work

My last two blogs compared a hypothetical example of reactive and proactive pharmacovigilance (PV). My next installment in this series outlines how PV can work. Rather than reacting to the data, in the second hypothetical scenario, Company A pivoted with ready-planned interventional pharmacovigilance practices at the level of the intake system and took a patient-centric […]


Perficient Wins Award for Its Pharmacovigilance Intelligence Solution

We are very excited to receive recognition for PV Hawk. Not only is it an honor, but it shows the value and flexibility of Perficient’s enthusiasm for bringing common sense to complex problems and the success of our cross-functional teams that contributed to getting this solution out. For many years, I, along with many others, […]


Proactive Pharmacovigilance: Another Real-World Example

My previous blog provided a hypothetical example of reactive pharmacovigilance. This blog will examine the opposite, proactive pharmacovigilance and the success it can bring. Company A launches a first-in-class drug/device combo biologic for the treatment of psoriatic arthritis. The drug has a novel mechanism of action. In clinical trials, ACR response was 26 weeks. The […]


Reactive Pharmacovigilance: A Real-World Example

Previously, I examined the best ways to overcome challenges with a new pharmacovigilance system. I now want to provide a hypothetical example of reactive pharmacovigilance. Company A launches a first-in-class drug/device combo biologic for the treatment of psoriatic arthritis. The drug has a novel mechanism of action. In clinical trials, the American College of Rheumatology […]

Scientists Discussing And Using Computer Software

Overcoming Challenges with a Pharmacovigilance System

My last blog outlined the potential for increased return on investments when pharmacovigilance is implemented. The next blog in this series discusses the best ways to overcome any challenges with new systems. Looking at a pharmacovigilance system holistically, there are interconnected, interdependent parts. Understanding how those individual parts function independently, as well as their impact […]


Pharmacovigilance: The Return on Investment

Previously, I analyzed the history of pharmacovigilance (PV), AEs and clinical therapeutics. This post examines the potential for increased return on investments when pharmacovigilance is implemented. All AE data holds value; how that value is determined takes an astute scientific approach to surveillance. In 2001, the medical literature began to include the results of a […]


Historical Perspective of AEs, Pharmacovigilance, and Clinical Therapeutics

My last bog talked about mitigating data overload with proactive pharmacovigilance (PV). The next blog in this series analyzes the history of PV, AEs and clinical therapeutics. As early as the 1980s, it was recognized that prostaglandins were important in renal function, especially in hypertensive patients. Prostaglandins preserve and maintain renal blood flow and thus […]


[Guide] Mitigate Data Overload with Proactive Pharmacovigilance

Surveillance of pharmacovigilance (PV) and product quality-complaint (PQC) data is not a new activity. For years we have known that adverse events temporal to drugs occur. Moreover, they are consistently underreported, impacting analysis of the data in unknown ways. Nearly every regulatory authority across the world has guidance and requirements in place for marketing authorization […]


Questions Regarding Pharmacovigilance Reporting During COVID-19

With the shift to working from home, changing daily priorities, and resources during the COVD-19 pandemic, regulators have or are making transitions to ease the stress without losing valuable data that may contribute to the treatment of COVID-19 or interrupting clinical trials. The pace at which the information on COVID-19 itself appears is so fast; […]


Pharmacovigilance During COVID-19: Finding the Best Information

There is no question that the pandemic COVID-19 has transformed life as we know it today. We are now operating in a different pharmacovigilance (PV) paradigm, adapting as we move daily. While patient safety remains the first priority, AEs will continue to come in for processing, and daily PV activities will continue. New therapeutic information […]

Acceptability Equals Mobility

MedDRA 23.0 – March Madness for the New Release

Each year in March (and September), we eagerly await the new releases of the MedDRA dictionary, hoping that any suggestions we have provided during the year were accepted. We also know that a significant dictionary change can be a bit much during a busy time. MedDRA 23.0 will be released on March 1, 2020. In […]

Load More